Document:

Exhibit

March 7, 2019 
______________
______________
______________

Dear Scott,

This letter agreement (this “Agreement”), which shall be effective as of March 5, 2019 (the “Effective Date”), sets forth the terms of your appointment as Executive Director of Immunomedics, Inc. (the “Company”), which was effective as of February 23, 2019. As Executive Director, you will be expected to perform your duties as a member of the Board of Directors of the Company (the “Board”) as well as consult with and advise the Company’s management team at the request of the Board from time to time with respect to your knowledge, experience and expertise.  This will include (1) assisting the Company’s management team with resolving the issues identified in the Complete Response Letter received from the U.S. Food and Drug Administration (the “FDA”) related to the Biologics License Application (“BLA”) seeking accelerated approval of sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease; (2) assisting the Company’s management team in the preparation and resubmission of the BLA; and (3) such other matters as they relate to the foregoing and as reasonably designated to you by the Board (the “Services”).

As consideration for the Services as Executive Director, you will earn and be paid $16,667 per month.  The Company shall reimburse you for all reasonable expenses you incur in connection with the performance of the Services, including travel expenses, provided that you obtain the Company’s prior written approval. On the Effective date, the Company granted you, pursuant to the Immunomedics, Inc. 2014 Long-Term Incentive Plan (the “Plan”), an option to purchase 79,818 shares of the Company’s common stock (the “Performance-Based Option”) pursuant and subject to the Plan and a stock option agreement. The Performance Based Option is a nonqualified stock option, and has an exercise price per share equal to $16.96, the Fair Market Value (as defined in the Plan) of a share of common stock of the Company as of the date of grant pursuant to the terms of the Plan, and shall vest in full upon FDA approval of the BLA. 

You or the Company may terminate your position as Executive Director at any time, and for any reason, by providing written notice to the other party.

As Executive Director, you will not be considered an employee of the Company.  Hence, you shall not have the right to any of the pension, retirement or other benefit programs available to the Company’s regular employees.

The Company’s Board and management team are very excited about the opportunity to have you serve as Executive Director of the Company.  This is a critical time for the Company and we look forward to experiencing the Company’s future successes with you.  Please indicate your agreement to the foregoing by signing a copy of this Agreement where indicated below and returning it to us.

Very Truly Yours,

IMMUNOMEDICS, INC.

By: /s/ Jared Freedberg
Name: Jared Freedberg
Title: General Counsel 
Date: 3/7/19

Agreed to and Acknowledged:

By: /s/ Scott Canute
Name: Scott Canute
Date: 3/7/2019Exhibit

March 13, 2019

Michael Pehl
______________
______________
______________
Re: Separation from Employment
Dear Michael:

This confidential separation agreement and release (“Agreement”) sets forth the agreement reached concerning the termination of your employment with Immunomedics, Inc. (the “Company”). 

1.Separation Date.

(a)You acknowledge that, by letter dated February 22, 2019, you resigned from your positions as Chief Executive Officer and President of the Company and resigned from the Board of Directors of the Company, which resignations were accepted by the Company and effective as of February 23, 2019.

(b)It is agreed that your last day of employment with the Company will be March 25, 2019 (the “Separation Date”). On the next regularly scheduled payday following the Separation Date, you will receive your final paycheck reflecting employment through the Separation Date, as well as accrued but unused vacation, less applicable withholding taxes and deductions. In addition, you will be reimbursed for all customary and appropriate business-related expenses incurred by you prior to the Separation Date, which shall be subject to and paid in accordance with the Company’s standard expense reimbursement policies applicable to senior-level executives. 

(c)For the period from February 22, 2019 through the Separation Date, you will be placed on garden leave (the “Garden Leave Period”). During the Garden Leave Period, you will remain on Company payroll, paid at your current rate of pay, and agree to make yourself reasonably available to the Company, by phone or email, to assist in transition as the Company may deem necessary and appropriate, but you shall not report to the Company’s offices, access Company email or computer systems, or perform any work for or on behalf of the Company, except as expressly requested by the Company. For the avoidance of doubt, during the Garden Leave Period you shall continue to comply fully with and be bound by all policies and procedures in effect for executives of the Company, including but not limited to all requirements contained in the employee handbook, and shall continue to comply fully with and be bound by all laws and regulations applicable to the business of the Company. Moreover, you shall not incur any business expenses during the Garden Leave Period, absent prior written authorization of the Company.

(d)You acknowledge that, as of February 23, 2019, you no longer serve as, and from that date shall not hold yourself out as, an officer, director, executive, member, trustee, representative, or agent of the Company or of any parent, subsidiary, or affiliate of the Company, and that you no longer have authority to act on behalf of or as a legal representative of the Company or any parent, subsidiary, or affiliate of the Company. Moreover, on and after the Separation Date, you shall no longer serve or hold yourself out as an employee of the Company or any parent, subsidiary, or affiliate of the Company.

(e)Except as expressly set forth herein, all Company-provided benefits will terminate on the Separation Date, subject to the terms of the applicable benefit plans. Any accrued or vested amounts or benefits due to you will be treated in accordance with the applicable benefit plan, program, or policy. After the Separation Date, you may be eligible to elect continuation coverage under the Company’s group health insurance plans for yourself, your spouse, and your eligible dependents, in accordance with the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”), or applicable state law.

2.Severance Benefits. In consideration for your signing and not revoking this Agreement and complying with its terms, and in exchange for the promises, covenants, and waivers set forth herein, Immunomedics will provide you with the following separation benefits (collectively, the “Severance Benefits”):

(a)Cash severance in an amount equal to: (i) $960,000, reflecting eighteen (18) months of pay at your current base salary, plus (ii) $55,759, reflecting your Target Bonus for the current fiscal year, prorated based on your 

employment through the date of notice of resignation. The cash severance, less applicable withholdings and deductions, shall be paid in substantially equal installments over an 18-month period consistent with the Company’s regularly scheduled payroll, with the first installment being paid within sixty (60) days after the Separation Date, subject to your timely execution and non-revocation of this Agreement within 60-day period. Payments made under this Section 2(a) shall not be eligible to be contributed to any retirement, savings, or compensation plan and shall not be benefit-bearing compensation for purposes of any employee benefit plans of the Company.

(b)Provided that you timely and properly elect continuation coverage under COBRA, the Company shall, for a period of 18 months following the Separation Date, pay the premiums for COBRA healthcare continuation coverage for you and, as applicable, your spouse and eligible dependents, less an amount equal to the required monthly employee payment for such coverage, calculated as if you continued to be an employee of the Company throughout such period. The COBRA premiums to be paid by the Company under this Section 2(b) shall be remitted directly to the health insurance administrator. Any remaining COBRA premiums shall be your responsibility. Notwithstanding the foregoing, payments specified under this Section 2(b) shall cease if the Company’s statutory obligation to provide such COBRA healthcare continuation coverage terminates for any reason, including but not limited to your failure to timely elect continuation coverage under COBRA or your failure to timely pay your share of the COBRA premiums.

3.Equity.  Your outstanding equity grants shall be governed by and subject to the applicable terms and conditions set forth in your outstanding awards and the Immunomedics, Inc. 2014 Long-Term Incentive Plan provided that for purposes of your performance-based nonqualified stock option dated December 7, 2017, your termination shall be treated as Involuntary Termination (as defined in such award agreement).            

4.Acknowledgments. You agree and acknowledge that:

(a)You would not be entitled to the Severance Benefits set forth in this Agreement unless you sign and do not revoke this Agreement and comply with its terms. 

(b)The Severance Benefits provided above are in lieu of and in full satisfaction of any amounts that might otherwise be payable under any contract, plan, policy or practice, past or present, of Immunomedics or any of its affiliates, including but not limited to your Executive Employment Agreement dated November 8, 2017 (the “Employment Agreement”) and the Immunomedics Severance Pay Plan.

(c)Except as expressly set forth herein, you are not entitled to, and will not seek, any further compensation or consideration of any kind from the Company, including wages, bonus, commissions, severance, incentive compensation, equity, or benefits. 

(d)If you decline to execute this Agreement, revoke this Agreement following execution, or fail to comply with the terms and conditions of this Agreement, all payments under Section 2 shall immediately cease and you shall be required to repay immediately any cash severance previously paid by the Company thereunder. 

5.Release. 

(a)In consideration of the payment and arrangements described in Section 2 above and for other good and valuable consideration, you, individually and on behalf of yourself, your heirs, executors, administrators, successors, and assigns, knowingly and voluntarily hereby release and forever discharge the Company and its affiliates, related entities, parents, subsidiaries, and divisions, and each of their past, present, or future officers, directors, members, partners, managers, stockholders, employees, agents, investors, and advisors, and each of their respective predecessors, successors and assigns, and any and all employee pension or welfare benefits plans of the Company, including current and former trustees and administrators of these plans (collectively, the “Released Parties”) from any and all claims, liabilities, demands, causes of action, costs, expenses, attorney fees, damages, indemnities and obligations of every kind and nature, in law, equity or otherwise, known and unknown, suspected and unsuspected, disclosed and undisclosed, arising from or relating to your employment with the Company and the termination of that employment. 

(b)Without limiting the generality of the foregoing, this Release includes, but is not limited to, (i) any rights or claims arising under any federal, state, or local constitution, statute, ordinance, or regulation, including without limitation, Title VII of the Civil Rights Act of 1964, the Civil Rights Act of 1991, the Civil Rights Act of 1866, Section 1981 through 1988 of Title 42 of the United States Code, the Americans with Disabilities Act of 1990, the Genetic Information Nondiscrimination Act of 2008, the Family and Medical Leave Act of 1993, the Equal Pay Act, the Lilly Ledbetter Fair Pay Act, the Age Discrimination in Employment Act of 1967 (the “ADEA”), the Older Workers Benefit 

Protection Act (“OWBPA”), the Rehabilitation Act of 1973, the Employee Retirement Income Security Act of 1974,the anti-retaliation provisions of the Fair Labor Standards Act, the Worker Adjustment Retraining and Notification (“WARN”) Act and any state WARN statutes, the Occupational Safety and Health Act, the Uniformed Services Employment and Reemployment Rights Act, the anti-retaliation provisions of the Corporate and Criminal Fraud Accountability Act of 2002, 18 U.S.C. § 1514A (also known as the Sarbanes-Oxley Act and/or Dodd-Frank Wall Street Reform Consumer Protection Act), the Fair Credit Reporting Act, the New Jersey Law Against Discrimination, the New Jersey Family Leave Act, the Conscientious Employee Protection Act, and the New Jersey Wage Laws, each of the foregoing as amended; (ii) any rights or claims under any plan, program, policy, agreement, contract, understanding or promise, express or implied, written or oral, formal or informal, between the Company or any of the Released Parties and myself, including but not limited to the Employment Agreement; (iii) any claim for unpaid compensation, wages, bonus or incentive compensation, profits, commission, equity, securities, benefits, vacation, severance pay, and/or other fringe benefit of the Company or any of the other Released Parties; (iv) any rights or claims under any common law theory, including for alleged tortious, negligent, defamatory and/or fraudulent conduct; and (v) any claim for equitable relief or recover of punitive, compensator, or other damages or monies, including attorney’s fees or costs.

(c)Notwithstanding the foregoing, nothing in this Agreement will serve to waive or impair (i) any claims or rights that, pursuant to law, cannot be legally waived or subject to a release of this kind, such as claims for unemployment or workers’ compensation benefits or claims under the ADEA that arise after you sign this Agreement, (ii) any rights you may have to  vested benefits under any applicable Immunomedics retirement plan or options under any equity plans of the Company as of the Separation Date subject to the terms and conditions applicable to such outstanding options, (iii) any claims or rights you may have to indemnification and/or coverage under Company D&O policy under which you are covered as an “insured person” as of the Separation Date, or (iv) any right you may have to bring appropriate proceedings to enforce this Agreement. In addition, nothing in this letter limits or waives your right to seek a judicial determination of the validity of the Release’s waiver of claims under the ADEA.

6.No Suits. You hereby represent and warrant that you have not filed, caused to be filed or permitted to be filed any complaints, charges, lawsuits or other proceedings against the Company or any of the other Released Parties, and that no such complaints, charges, lawsuits or other proceedings are pending. You further agree not to initiate any legal action or proceeding against the Company or the Released Parties in any forum in connection with the claims released by you. That said, nothing in this letter prohibits you from filing a charge with or participating in any investigation or proceeding conducted by the Equal Employment Opportunity Commission or a comparable state or local agency (“EEOC”) or with the Securities and Exchange Commission. You further agree that if you, or anyone on your behalf, files a charge with the EEOC, civil action, suit or legal proceeding against the Released Parties involving any matter subject to the Release you waive your right to seek or recover any personal relief (including but not limited to monetary damages) in such proceeding; provided, however, that this limitation on recovery shall not apply to administrative proceedings before the SEC. 

7.Return of Company Property. You represent and warrant that, on or before the Separation Date, you shall return to the Company all property belonging to the Company, including but not limited to computers, mobile phones, electronic devices, entry badges and keys, passwords and log-in credentials, documents, records, files, and equipment that is in your possession, custody, or control.

8.Cooperation. Following the Separation Date, and in consideration of the Severance Benefits, you agree to cooperate with the Company in (a) responding to reasonable requests by the Company for information concerning work performed or actions taken by you during your employment with the Company or with regard to any matters about which you may have knowledge; and (b) any investigation or review that may be performed by the Company or any government authority or in connection with any litigation in which the Company may become involved which relates to the business of the Company during the period of your employment or events or occurrences about which you may have knowledge. The Company will reimburse you for reasonable expenses incurred by you in providing such cooperation. Moreover, upon service on you, or anyone acting on your behalf, of any subpoena, order, directive, or other legal process in any way relating to Immunomedics, you or your attorney shall immediately notify Immunomedics in writing (unless prohibited to do so by law) of such service and of the content of any testimony or information to be provided pursuant to such a subpoena, order, directive or other legal process and within two (2) business days send to the undersigned representative of Immunomedics via email or overnight delivery (which expense shall be reimbursed by Immunomedics) a copy of said documents served upon you. You agree to cooperate with Immunomedics in any effort Immunomedics undertakes to obtain a protective order or other remedy in connection with such subpoena, order, directive, or other legal process.

9.Continuing Obligations. You agree to comply with all obligations under the Employment Agreement that survive the Separation Date, including but not limited to the obligations in Sections 5 (Confidentiality), 6 (Intellectual Property), 7 (Non-Competition), and 8 (Non-Solicitation), as further clarified by Section 9 (General Provisions) (collectively, the “Continuing Obligations”). You understand and acknowledge that your right to the Severance Benefits outlined herein is subject to your continued compliance with the Continuing Obligations. 

10.Non-Disparagement. You agree not to make, or knowingly cause to be made, any statement or communication, written or oral, with the intention of disparaging or otherwise impugning the business or management of, or with the intention of damaging the reputation of or interfering with the normal operations of, Immunomedics or the Released Parties. You further agree not to communicate with, give interviews and/or provide statements either directly or indirectly, to any member of the media concerning any aspect of your employment or experiences with Immunomedics (including the cessation of your employment) or in any way concerning the Immunomedics’ business, its business model and/or its operations. Nothing in this Agreement will (i) affect your obligations to provide truthful information on any non-privileged subject matter in response to a valid subpoena, court order, regulatory request or other judicial, administrative or legal process or otherwise as required by law or (ii) unlawfully impair or interfere with your rights under Section 7 of the National Labor Relations Act.

11.Non-Disclosure of Agreement. You agree not to disclose the terms, content, or execution of this Agreement, except that you may disclose the terms of this Agreement: (i) to your immediate family, attorney, and tax and financial advisors, so long as such individuals agree to be bound by the confidential nature of this Agreement, (ii) pursuant to a valid subpoena, court order, regulatory request or other judicial, administrative or legal process or otherwise as required by law, or (iii) for purposes of securing enforcement of the terms and conditions of this Agreement. Nothing in this Agreement is intended to or will preclude you from reporting, without any prior authorization from or notification to Immunomedics, possible violations of federal law or regulation to any governmental agency or entity, including but not limited to the Department of Justice, the Securities and Exchange Commission, Congress, and any agency Inspector General, or making other disclosures that are protected under the whistleblower provisions of federal law or regulation.

12.Contents of Agreement, Amendment, Interpretation. 

(a)This Agreement constitutes the entire agreement between Immunomedics and you, and supersedes and cancels all prior written and oral agreements, if any, between Immunomedics and you; provided, however, that nothing in this Agreement will impair your obligations under the Employment Agreement, which survive the Separation Date. You affirm that, in entering into this Agreement, you are not relying upon any oral or written promise or statement made by anyone at any time on behalf of Immunomedics.

(b)This Agreement cannot be changed or modified except by a writing signed by an authorized representative of Immunomedics and you. 

(c)The headings in this Agreement are for convenience only, and both parties agree that they shall not be construed or interpreted to modify or affect the construction or interpretation of any provision of this Agreement. 

(d)It is the desire and intent of the parties that the provisions of this Agreement shall be enforced to the fullest extent permissible under the laws and public policies applied in each jurisdiction in which enforcement is sought. In the event that any one or more of the provisions of this Agreement shall be held to be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby; however, if the Release in Section 5 is held to be invalid, illegal, or unenforceable, then you agree that (i) you will be required to enter into a new agreement containing an enforceable release of all legally waivable claims against the Company and the Released Parties; and (ii) the Severance Benefits will constitute sufficient consideration for your entering into such new agreement.

(e)No waiver by either party of any breach by the other party of any condition or provision of this Agreement to be performed by such other party shall be deemed a waiver of any other provision or condition at the time or at any prior or subsequent time. 

13.Miscellaneous.

(a)This Agreement is binding upon and shall inure to the benefit of your successors, assigns, heirs, executors, administrators, and legal representatives, and shall be binding on and inure to the benefit of the Company’s successors and assigns.

(b)This Agreement may be executed in counterparts, each of which will be deemed an original but all of which together will constitute one and the same instrument, notwithstanding that all of the parties are not signatory to the same counterpart. This Agreement may be executed either by original, facsimile or electronic copy, each of which will be equally binding.

(c)This Agreement shall be governed by and interpreted under the laws of the State of New Jersey without giving effect to any conflicts-of-law provisions or canons of construction that construe agreements against the draftsperson. Each party hereby irrevocably submits to the exclusive jurisdiction of the United States District Court located in New Jersey or any state court located within such state, in respect of any claim arising out of or relating to this Agreement or Executive’s employment with the Company. SUBJECT TO APPLICABLE LAW, THE PARTIES HEREBY WAIVE ANY RIGHT TO A JURY TRIAL WITH RESPECT TO ANY DISPUTE ARISING FROM OR RELATING TO THIS AGREEMENT.

14.Section 409A. Although the Company makes no guarantee with respect to the tax treatment of payments hereunder, payments under this Agreement are intended to either comply with, or be exempt from, the provisions of the Internal Revenue Code Section 409A and the treasury regulations, guidance, and exemptions promulgated thereunder (collectively, “Section 409A”) so as not to subject you to the payment of any tax, interest, or penalty that may be imposed under Section 409A. Notwithstanding the foregoing, the Company shall have (i) no obligation to prevent, minimize, or make a gross-up payment to offset any negative consequences to you under Section 409A and (ii) no liability to you for any negative consequences if they arise.

15.Review and Acknowledgment. By signing below, you acknowledge that: 
(a)You have read this Agreement and understand its terms;

(b)You are fully competent to sign this Agreement and do so freely and voluntarily without any coercion or undue influence from anyone;

(c)The payments and other consideration being provided to you are of significant value and in addition to what you otherwise would be entitled to receive from the Company, but for your execution of this Agreement;

(d)By way of this Agreement, the Company has advised you of your right to consult with an attorney of your choosing concerning the legal significance of this Agreement prior to signing it;

(e)You have been given 21 days to review and consider this letter before signing it, though you may voluntarily sign it early. If you do not sign this letter within 21 days, it shall have no effect. Any changes to this letter, whether material or otherwise, will not re-start the 21 day period;

(f)After signing this Agreement, you may revoke your acceptance by delivering written notice by email of the election to the Company, [Attn: Jared Freedberg, General Counsel], not later than 7 days after the date you sign the Agreement. If not revoked within 7 days, this Agreement will become fully effective and irrevocable on the eighth day after the date you sign the Agreement. If you revoke your acceptance, you acknowledge that this Agreement shall be null and void and you shall have no rights to arrangements or benefits set forth above.

[SIGNATURES APPEAR ON FOLLOWING PAGE]    

IN WITNESS WHEREOF, the undersigned, intending to be legally bound, have executed this Agreement as of the date first above written. 

IMMUNOMEDICS, INC.
                            
By:  /s/ Jared Freedberg
   Name: Jared Freedberg
   Title: General Counsel

                            

MICHAEL PEHL
                            
/s/ Michael Pehl
Michael Pehl

Date:  03/13/2019

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00295-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00295-of-00352.parquet"}]]